Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 52: 1606-1608, 2006; 10.1373/clinchem.2006.069476
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holmes, D. T.
Right arrow Articles by Buhr, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holmes, D. T.
Right arrow Articles by Buhr, K.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
(Clinical Chemistry. 2006;52:1606-1608.)
© 2006 American Association for Clinical Chemistry, Inc.


Letters to the Editor

Mathematical Modeling: Assumptions Affect Results

Daniel T. Holmes1,a and Kevin Buhr2

1 St. Paul’s Hospital, Department of Laboratory Medicine, and the Department of Pathology, University of British Columbia, Vancouver, BC, Canada
2 Department of Mathematics, University of British Columbia, Vancouver, BC, Canada

aAddress correspondence to this author at: St. Paul’s Hospital Department of Laboratory Medicine and the University of British Columbia Department of Pathology. 1081 Burrard Street, Vancouver, BC, Canada, V6Z 1Y6. Fax 604-806h8815; e-mail dtholmes@interchange.ubc.ca.

The first 20% of the full text of this article appears below.


To the Editor:

Apple et al. (1) recently presented an analysis of the effect of imprecision (CV) on false positive cardiac troponin I (cTnI) results. After examining their methodology, we have identified problems with the model and arguments.

Key mathematical details are omitted, and some assumptions appear unrealistic. The authors model the plasma cTnI concentrations in a healthy reference population by an exponential distribution and the analytical error as gaussian using 2 assumed CV profiles: a baseline profile and the same scaled by a factor of 0.40. We observe 2 difficulties.

First, the baseline profile is incompletely specified, and the points provided (CVs of 37.5%, 25.0%, and 9.4% at true cTnIs of 0.05, 0.07, and 0.14 µg/L) imply SDs that decrease with increasing cTnI, which does not reflect reality (2)(3). Further, the "SD of the blank" (cTnI = 0 µg/L) is entirely unspecified. To contrast, we constructed empirical profiles using mean concentration data and CVs from a recent paper comparing 15 cTnI assays (4). Fig. 1a compares the 5 cTnI assays whose data overlap the concentration range 0.05–0.14 µg/L to those used by Apple et al. . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.